Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00780052 · ClinicalTrials.gov registry record · Phase 1
Infusional C-myb ASODN in Advanced Hematologic Malignancies
A Phase 1 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT00780052 is a Phase 1 study that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 13 participants.
The verdict
NCT00780052, a Phase 1 study, has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.
Interventions
- DRUG c-myb AS ODN
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2002-09 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00780052
The ClinicalTrials.gov registry entry for NCT00780052 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which c-myb AS ODN is the first listed.
NCT00780052 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00780052 about?
NCT00780052 is a clinical study titled "Infusional C-myb ASODN in Advanced Hematologic Malignancies". The purpose of this study is to evaluate whether C-myb Antisense (AS) Oligonucleotides (ODNs)is a possible treatment modality for advanced hematologic malignancies.
What is the current status of trial NCT00780052?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2002-09. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00780052?
The interventions under investigation include: c-myb AS ODN (DRUG).
Who is sponsoring clinical trial NCT00780052?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.